Introduction {#section5-2042018820937896}
============

Hypothyroidism affects approximately 5% of the United States population, and synthetic thyroxine in the form of levothyroxine (LT4) is the most prescribed therapy for this common condition.^[@bibr1-2042018820937896],[@bibr2-2042018820937896]^ Autoimmune hypothyroidism is generally progressive, with a decrement in endogenous thyroid function occurring over time, such that overt hypothyroidism would occur if the thyroid hormone deficiency is untreated.^[@bibr3-2042018820937896]^ However, at the current time hypothyroidism may initially be diagnosed when it is mild or subclinical, at a time that the serum thyroid stimulating hormone (TSH) is minimally elevated below 10 mIU/L and the serum thyroid hormone levels are normal. Symptoms of hypothyroidism are not always specific for this condition, and each of the symptoms generally associated with hypothyroidism may also have non-thyroid causes.^[@bibr4-2042018820937896]^ As attribution of the cause of symptoms is not a simple matter,^[@bibr5-2042018820937896],[@bibr6-2042018820937896]^ many physicians may err on the side of treating mild TSH elevations with the expectation that symptoms may improve. Thus, treatment with LT4 may be initiated for borderline TSH elevations.^[@bibr7-2042018820937896]^ The authors also hypothesize that LT4 may even be prescribed for unconfirmed serum TSH elevations, or even without TSH elevation, based on the symptoms that the patient is experiencing.

LT4 is being prescribed with increasing frequency, both in the United States^[@bibr8-2042018820937896],[@bibr9-2042018820937896]^ and in other countries.^[@bibr10-2042018820937896],[@bibr11-2042018820937896]^ Several studies have shown that the TSH threshold at which LT4 therapy is initiated has fallen over time, such that an increasing number of cases of subclinical hypothyroidism are being treated and the mean or median TSH value at which therapy is initiated has decreased over time.^[@bibr7-2042018820937896],[@bibr12-2042018820937896][@bibr13-2042018820937896]--[@bibr14-2042018820937896]^ This trend for increasing treatment and decreasing thresholds has been documented both in the United States^[@bibr9-2042018820937896],[@bibr14-2042018820937896]^ and in Europe.^[@bibr7-2042018820937896],[@bibr12-2042018820937896],[@bibr13-2042018820937896]^ Moreover, a recent study showed that if LT4 therapy was discontinued in patients undergoing treatment, while 39% of patients did in fact become hypothyroid as manifest by an elevated TSH, 61% maintained a normal TSH, perhaps suggesting that their treatment was unnecessary.^[@bibr15-2042018820937896]^ However, the follow-up period in this study was relatively brief at 6--8 weeks, thus hypothyroidism being manifest later during follow-up cannot be excluded.^[@bibr15-2042018820937896]^ Although national databases show a trend for an increasing number of LT4 prescriptions being provided over time,^[@bibr16-2042018820937896],[@bibr17-2042018820937896]^ part of this apparent increase may be accounted for by a reduction in the length of prescriptions by prescribers,^[@bibr10-2042018820937896]^ such that more prescriptions are being generated for the same number of patients each year.

The current analysis examined the prescription of LT4 using the electronic medical record (EMR) of a large health care system (MedStar) operating in the Washington, DC and Maryland area. The MedStar Health System is a non-profit healthcare organization founded in 1998. It operates several physician practice groups and also 10 hospitals in the Baltimore--Washington metropolitan area. Approximately 5000 physicians provide medical care within this system. The MedStar Health System also operates the MedStar Health Research Institute, which employs scientists and investigators engaged in translational and health sciences research. The patient population is likely representative of the general population in terms of age, sex, and socioeconomic status, based on datasets such as the United States Census.^[@bibr18-2042018820937896]^ The EMR, which is the system in use by all MedStar physicians, was interrogated to determine whether the number of prescriptions being provided for LT4 was changing over time, what the associated diagnosis was, and also to examine prescriptions according to patient age and sex.

Methods {#section6-2042018820937896}
=======

The study was approved by the joint Georgetown University--MedStar Institutional Review Board (study number 2017-0335). Waiver of the need to obtain informed consent from participants was granted. Data extraction was performed by the Biostatistics and Biomedical Informatics component of the Clinical and Translation Science Award program at Georgetown University using Medstar Health Research Institute Databases, including Centricity and Explorys as appropriate. Centricity is an ambulatory care electronic medical record system which can be used for clinical research, including performing retrospective cohort studies. Explorys is a system that interacts with electronic medical records systems and allows for secure storage and analysis of large patient data sets in a manner compliant with ethical regulations. The databases were searched for the years 2008--2016, a period during which significant changes to the database were not occurring. Adult outpatients 18 years and older were included in the search. All LT4 products were searched for, including the following: Levothyroxine, Synthroid, Unithroid, Levoxyl, and Levothroid. The doses of LT4 products that were included were 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 µg. Data regarding other thyroid hormone preparations such as armour thyroid, desiccated thyroid extract, liothyronine (Cytomel) were not collected as these were a small proportion of thyroid hormone prescriptions.

Diagnoses of hypothyroidism, and all diagnoses potentially associated with hypothyroidism, were documented using International Classification of Diseases (ICD) codes. Both ICD -9 and ICD-10 codes were noted. These included, for example, diagnoses of thyroid cancer, Hashimoto's thyroiditis, and thyroidectomy. The design of the EMR encourages physicians to be as complete and comprehensive as possible in assigning all relevant diagnoses. Such diagnoses were noted if they were present at any time and linked to any visits in the patient's electronic chart. Patients with any of the multiple diagnostic codes for hyperthyroidism were excluded from the analysis, as were hospitalized patients, pediatric patients, and pregnant patients. Prescriptions were classified as pre-existing if any dose of LT4 had been prescribed before, even if there had been a hiatus or a change in dose. Prescriptions were classified as new if no dose of LT4 had been prescribed before. All LT4 prescriptions were normalized to a 90-day period.

The following information was extracted from the electronic medical record:

1.  The number of patients in the database annually;

2.  The number of patients being prescribed levothyroxine in the database annually;

3.  The average age and age distribution of the patients in the database annually;

4.  The average age and age distribution of the patients in the database being prescribed levothyroxine annually;

5.  The number of levothyroxine prescriptions in the database annually;

6.  The number of levothyroxine prescriptions per patient annually;

7.  The duration of each levothyroxine prescription in number of days on an annual basis;

8.  The sex distribution of patients being prescribed levothyroxine annually;

9.  The presence or absence of a diagnosis of hypothyroidism in the patients being prescribed levothyroxine annually;

10. The average levothyroxine dose and distribution of levothyroxine doses annually;

11. The average TSH value and TSH distribution associated with the first levothyroxine prescription in each patient annually.

Statistical analysis {#section7-2042018820937896}
--------------------

This was a study to determine whether LT4 prescribing was increasing within this population in the same way that has been described nationally, and to determine which factors seemed to be associated with any LT4 prescribing trends observed in this geographic area of the United States. All data extracted from the EMR was summarized using descriptive statistics (mean, standard deviation, median, range for continuous variables, and frequencies and percentages for categorical variables). Factors examined included patient age and sex, and TSH values. Prescriptions were divided according to whether they were written for a diagnosis of hypothyroidism, or written for patients without a diagnosis of hypothyroidism. LT4 prescribing across the age spectrum was examined. Statistical analyses were conducted using the statistical expertise of the Department of Biostatistics and Bioinformatics at MedStar Health Research Institute.

Results {#section8-2042018820937896}
=======

The number of outpatients within the MedStar system increased from 135,150 in 2008 to 547,433 patients in 2016. The number of outpatients being prescribed LT4 increased from 8229 in 2008 to 20,089 in 2016. Using the outpatient population as a denominator, the percent of patients being prescribed LT4 was 6.1% in 2008 and decreased to 3.7% in 2016 (see [Figure 1](#fig1-2042018820937896){ref-type="fig"}). Outpatients were also divided according to whether or not they had a diagnosis of hypothyroidism documented in their EMR. The percentage of patients being prescribed LT4 with a documented diagnosis of hypothyroidism increased from 2.5% in 2008 to 3.2% in 2012 and then decreased to 2.5% in 2016. The percentage of patients being prescribed LT4 without a diagnosis of hypothyroidism decreased from 3.6% in 2008 to 1.1% in 2016 (see [Figure 2](#fig2-2042018820937896){ref-type="fig"}).

![Percentage of patients being prescribed levothyroxine between 2008 and 2016.](10.1177_2042018820937896-fig1){#fig1-2042018820937896}

![Percentage of patients being prescribed levothyroxine between 2008 and 2016, divided according to whether they carried a diagnosis of hypothyroidism or not.](10.1177_2042018820937896-fig2){#fig2-2042018820937896}

LT4 doses being prescribed {#section9-2042018820937896}
--------------------------

When the LT4 prescriptions were categorized according to the dose being prescribed, the most commonly prescribed doses were 50, 75, 100, and 125 µg. This pattern was seen regardless of whether or not a diagnosis of hypothyroidism was documented in the patient's chart (see [Tables 1](#table1-2042018820937896){ref-type="table"} and [2](#table2-2042018820937896){ref-type="table"}). The 50 µg dose was prescribed for the highest percentage of patients, the percentage being 14.6--16.8% in all patients, 15.1--16.7% in those patients without documentation of hypothyroidism, and 14.1--17.1% in patients with documentation of hypothyroidism.

###### 

Levothyroxine prescriptions divided by the percentage of each dose that was prescribed on an annual basis.

![](10.1177_2042018820937896-table1)

  Percentage of each dose prescribed per year                                                                   
  --------------------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  25                                            6.35    6.61    6.70    7.78    8.10    8.64    8.48    8.52    8.35
  50                                            15.00   14.60   14.91   15.56   16.51   16.82   16.40   16.63   16.51
  75                                            14.70   13.74   14.15   14.34   14.60   14.78   15.15   15.19   15.49
  88                                            7.09    7.29    7.63    7.96    8.52    8.59    8.73    8.74    9.23
  100                                           15.96   15.67   14.63   14.76   14.23   14.10   14.37   14.30   14.27
  112                                           8.12    8.53    8.60    8.64    7.99    8.15    8.16    8.08    8.48
  125                                           10.57   10.87   10.68   9.77    9.93    9.45    9.41    9.23    9.02
  137                                           4.20    4.86    4.93    4.76    4.72    4.39    4.54    4.80    4.62
  150                                           8.79    8.53    8.23    7.74    7.31    6.96    6.81    6.77    6.60
  175                                           4.70    4.61    4.99    4.61    4.35    4.53    4.45    4.31    4.17
  200                                           4.16    4.23    4.11    3.67    3.44    3.34    3.29    3.25    3.00
  300                                           0.37    0.47    0.44    0.40    0.30    0.24    0.22    0.19    0.26

Gray shading indicates the most frequently prescribed doses. LT4, levothyroxine.

###### 

Levothyroxine prescriptions divided by the percentage of each dose that was prescribed on an annual basis, and subdivided by whether a diagnosis of hypothyroidism was documented or not.

![](10.1177_2042018820937896-table2)

  LT4 dose (µg)   Percentage of each LT4 dose prescribed per year                                                                                                                   
  --------------- ------------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  25              6.8                                               5.7    7.3    5.8    7.3    6.2    8.1    7.5    8.1    8.1    9.0    8.4    8.5    8.5    8.5    8.5    8.2    8.4
  50              15.6                                              14.2   15.1   14.1   15.0   14.9   15.4   15.7   16.0   16.8   16.7   16.9   15.7   16.8   15.6   17.1   15.5   16.9
  75              14.8                                              14.5   14.0   13.4   14.6   13.8   15.0   13.8   14.7   14.5   15.2   14.5   15.9   14.8   15.4   15.1   15.7   15.4
  88              7.7                                               6.3    7.2    7.3    8.2    7.2    8.2    7.8    9.2    8.0    9.1    8.3    9.1    8.5    9.4    8.4    9.7    9.0
  100             16.2                                              15.6   15.8   15.5   15.3   14.1   16.2   13.6   14.9   13.7   14.7   13.8   14.9   14.1   14.7   14.1   15.1   14.0
  112             8.3                                               7.8    8.7    8.3    8.8    8.4    9.0    8.3    8.1    7.9    8.2    8.1    8.7    7.9    8.8    7.7    9.0    8.3
  125             10.1                                              11.2   11.0   10.8   11.1   10.3   9.1    10.3   10.0   9.9    9.3    9.6    9.4    9.4    9.1    9.3    9.0    9.0
  137             3.6                                               5.0    4.3    5.5    4.4    5.4    4.4    5.1    4.7    4.7    4.2    4.5    4.2    4.7    4.8    4.8    4.7    4.6
  150             8.7                                               9.0    8.1    8.9    7.2    9.1    7.3    8.1    7.0    7.5    6.7    7.1    6.8    6.8    6.4    7.0    6.4    6.7
  175             4.1                                               5.5    4.1    5.1    4.6    5.3    4.1    5.0    4.1    4.5    4.2    4.7    4.0    4.7    4.4    4.3    4.2    4.2
  200             3.7                                               4.8    3.9    4.6    3.2    4.9    2.9    4.3    2.8    3.9    2.6    3.8    2.6    3.6    2.7    3.5    2.5    3.2
  300             0.3                                               0.4    0.3    0.6    0.3    0.5    0.3    0.4    0.3    0.3    0.2    0.3    0.2    0.3    0.2    0.2    0.2    0.3

Gray shading indicates the most frequently prescribed doses.

LT4, levothyroxine

Patient age at prescription initiation {#section10-2042018820937896}
--------------------------------------

For patients whose LT4 prescription was initiated during the period of observation, the age of the patient at prescription initiation was noted. The mean age at initiation for all patients remained constant over the years 2008--2016 at age 54--57 years \[see [Table 3(a)](#table3-2042018820937896){ref-type="table"}\]. When patients were divided into age deciles, prescription initiation was observed at all deciles, but with the least number of prescriptions being initiated in the 18--29 and 80 years and older age groups \[see [Table 4(a)](#table4-2042018820937896){ref-type="table"} and [Figure 3](#fig3-2042018820937896){ref-type="fig"}\]. When patients were divided according to whether or not a diagnosis of hypothyroidism was documented in their EMR, the trend for age at initiation and age decile at initiation were similar for patients with a hypothyroidism diagnosis and those without \[see [Tables 3(b)](#table3-2042018820937896){ref-type="table"} and [4(b)](#table3-2042018820937896){ref-type="table"} and [Tables 3(c) and 4(c)](#table3-2042018820937896){ref-type="table"} respectively\].

###### 

Patient age at first initiation of a levothyroxine prescription on an annual basis, with patients divided according to whether they carried a diagnosis of hypothyroidism or not.

![](10.1177_2042018820937896-table3)

  -------------------------------------------------------------------------------------------------------
  Patient group                           Year   Patients\   Patient age                            
                                                 *n*                                                
  --------------------------------------- ------ ----------- ------------- ---- ---- ---- ---- ---- -----
  \(a\) All patients                      2008   4376        55            17   55   42   66   18   99

                                          2009   3639        54            17   54   41   65   18   100

                                          2010   2905        54            17   54   41   65   18   110

                                          2011   4911        55            17   55   43   67   18   101

                                          2012   5099        55            17   56   43   68   18   104

                                          2013   4967        57            18   57   44   70   18   108

                                          2014   4634        55            18   56   41   67   18   114

                                          2015   4078        54            17   55   40   66   18   97

                                          2016   3237        54            18   55   40   67   18   104

  \(b\) Patients with hypothyroidism      2008   1591        52            17   52   39   64   18   99

                                          2009   1645        53            17   53   40   64   18   99

                                          2010   1561        53            17   53   40   63   18   109

                                          2011   2453        54            17   54   41   65   18   101

                                          2012   2924        54            17   55   41   66   18   100

                                          2013   2926        55            18   55   42   67   18   108

                                          2014   2983        53            18   54   39   65   18   99

                                          2015   2767        52            17   53   38   64   18   97

                                          2016   2439        53            18   54   39   66   18   98

  \(c\) Patients without hypothyroidism   2008   2785        56            17   56   44   68   18   98

                                          2009   1994        54            17   55   41   66   18   100

                                          2010   1344        55            17   55   43   66   18   110

                                          2011   2458        56            17   56   45   68   18   99

                                          2012   2175        57            17   58   45   69   18   104

                                          2013   2041        60            19   60   47   75   18   104

                                          2014   1651        58            19   59   45   72   18   114

                                          2015   1311        57            18   58   44   69   18   97

                                          2016   798         56            18   57   42   69   18   104
  -------------------------------------------------------------------------------------------------------

pctl, percentile

###### 

Number of patients with first initiation of a levothyroxine prescription, divided according to age deciles, with patients divided according to whether they carried a diagnosis of hypothyroidism or not.

![](10.1177_2042018820937896-table4)

  Patient group                           Age decile   Number of patients with prescription initiation per year                                                 
  --------------------------------------- ------------ ---------------------------------------------------------- ----- ----- ------ ------ ------ ------ ----- -----
  \(a\) All patients                      18--29       340                                                        344   248   364    422    383    439    407   325
                                          30--39       584                                                        512   398   579    627    552    612    589   464
                                          40--49       746                                                        612   526   865    806    743    686    612   520
                                          50--59       973                                                        816   680   1130   1134   1083   1010   869   635
                                          60--69       823                                                        679   524   999    996    896    876    825   633
                                          70--79       505                                                        367   287   530    646    635    518    446   386
                                          80+          405                                                        309   242   444    468    675    493    330   274
  \(b\) Patients with hypothyroidism      18--29       164                                                        165   155   204    269    250    311    294   255
                                          30--39       235                                                        239   233   327    394    363    441    443   358
                                          40--49       297                                                        301   302   459    481    476    470    436   406
                                          50--59       364                                                        349   346   549    649    684    667    593   484
                                          60--69       270                                                        304   257   472    533    524    564    547   464
                                          70--79       149                                                        158   149   245    371    349    292    275   280
                                          80+          112                                                        129   119   197    227    280    238    179   192
  \(c\) Patients without hypothyroidism   18--29       176                                                        179   93    160    153    133    128    113   70
                                          30--39       349                                                        273   165   252    233    189    171    146   106
                                          40--49       449                                                        311   224   406    325    267    216    176   114
                                          50--59       609                                                        467   334   581    485    399    343    276   151
                                          60--69       553                                                        375   267   527    463    372    312    278   169
                                          70--79       356                                                        209   138   285    275    286    226    171   106
                                          80+          293                                                        180   123   247    241    395    255    151   82

![Age at levothyroxine (LT4) initiation divided by age decile and displayed on an annual basis.](10.1177_2042018820937896-fig3){#fig3-2042018820937896}

Age of all patients with LT4 prescriptions {#section11-2042018820937896}
------------------------------------------

When the age of patients being prescribed LT4, including both existing and new prescriptions, was examined, the mean age of patients ranged from 57 to 62 years of age \[[Table 5(a)--(c)](#table5-2042018820937896){ref-type="table"}\]. The age of patients being prescribed LT4 with a documented diagnosis of hypothyroidism tended to be a little younger (55--58 years) than those without this diagnosis (58--62 years) \[see [Table 5(b) and (c)](#table5-2042018820937896){ref-type="table"}\]. When displayed graphically ([Figure 4](#fig4-2042018820937896){ref-type="fig"}), more patients in the deciles of 50--59 years and 60--69 years had LT4 prescriptions, even though the mean age of the population only increased from 49 years to 51 years over the time period from 2008 to 2016 (see [Tables 4](#table4-2042018820937896){ref-type="table"} and [6](#table6-2042018820937896){ref-type="table"}).

###### 

Age of all patients with a levothyroxine prescription on an annual basis, with patients divided according to whether they carried a diagnosis of hypothyroidism or not.

![](10.1177_2042018820937896-table5)

  ---------------------------------------------------------------------------------------------------------------
  Patient group                           Year   Patients\   Age at prescription                            
                                                 *n*                                                        
  --------------------------------------- ------ ----------- --------------------- ---- ---- ---- ---- ---- -----
  \(a\) All patients                      2008   8229        57                    16   57   45   69   18   99

                                          2009   10,379      57                    17   57   45   68   18   100

                                          2010   11,289      57                    17   57   45   68   18   110

                                          2011   14,182      57                    16   57   46   68   18   111

                                          2012   16,825      58                    17   58   46   69   18   104

                                          2013   19,234      59                    17   59   47   70   18   109

                                          2014   20,823      59                    17   59   47   70   18   114

                                          2015   21,475      59                    17   59   48   70   18   115

                                          2016   20,088      59                    17   60   48   71   18   105

  \(b\) Patients with hypothyroidism      2008   3489        55                    16   55   43   66   18   99

                                          2009   5007        55                    17   55   43   66   18   99

                                          2010   6108        55                    16   56   43   66   18   109

                                          2011   7827        56                    16   56   44   67   18   101

                                          2012   9954        56                    16   57   44   68   18   102

                                          2013   12,001      57                    16   57   45   68   18   109

                                          2014   13,603      57                    16   58   46   68   18   110

                                          2015   14,584      57                    16   58   46   69   18   104

                                          2016   14,426      58                    16   59   47   69   18   105

  \(c\) Patients without hypothyroidism   2008   4740        59                    16   59   47   71   18   99

                                          2009   5372        58                    17   59   47   70   18   100

                                          2010   5181        59                    17   59   48   71   18   110

                                          2011   6355        59                    16   59   48   71   18   111

                                          2012   6871        60                    16   60   49   71   18   104

                                          2013   7233        61                    17   62   50   73   18   104

                                          2014   7220        62                    17   62   51   73   18   114

                                          2015   6891        62                    17   63   51   73   18   115

                                          2016   5662        62                    17   63   52   74   19   104
  ---------------------------------------------------------------------------------------------------------------

pctl, percentile

![Age of all patients with levothyroxine (LT4) prescriptions divided by decile and displayed on an annual basis.](10.1177_2042018820937896-fig4){#fig4-2042018820937896}

###### 

Number of all patients with a levothyroxine prescription, divided according to age deciles, with patients divided according to whether they carried a diagnosis of hypothyroidism or not.

![](10.1177_2042018820937896-table6)

  Patient group                           Age decile   Number of patients with prescriptions per year                                                    
  --------------------------------------- ------------ ------------------------------------------------ ------ ------ ------ ------ ------ ------ ------ ------
  \(a\) All patients                      18--29       420                                              579    584    707    852    910    962    979    867
                                          30--39       927                                              1229   1264   1472   1706   1826   2002   2072   1952
                                          40--49       1337                                             1636   1812   2305   2583   2843   2960   3000   2750
                                          50--59       1871                                             2354   2614   3287   3848   4328   4639   4667   4228
                                          60--69       1704                                             2195   2439   3151   3795   4281   4707   5042   4710
                                          70--79       1100                                             1306   1394   1788   2286   2767   3036   3209   3194
                                          80+          867                                              1076   1176   1458   1734   2254   2481   2462   2337
  \(b\) Patients with hypothyroidism      18--29       225                                              325    371    436    560    630    691    734    692
                                          30--39       440                                              663    779    921    1140   1276   1459   1578   1544
                                          40--49       617                                              878    1091   1397   1657   1926   2107   2198   2114
                                          50--59       817                                              1147   1424   1840   2329   2811   3152   3284   3149
                                          60--69       690                                              1035   1264   1673   2129   2600   3028   3392   3367
                                          70--79       395                                              535    651    897    1273   1611   1835   2006   2128
                                          80+          305                                              424    526    662    866    1146   1330   1391   1431
  \(c\) Patients without hypothyroidism   18--29       195                                              254    213    271    292    280    271    245    175
                                          30--39       487                                              566    485    551    566    550    543    494    408
                                          40--49       720                                              758    721    908    926    917    853    802    636
                                          50--59       1054                                             1207   1190   1447   1519   1517   1487   1383   1079
                                          60--69       1014                                             1160   1175   1478   1666   1681   1679   1650   1343
                                          70--79       705                                              771    743    891    1013   1156   1201   1203   1066
                                          80+          562                                              652    650    796    868    1108   1151   1071   906

Sex of patients with LT4 prescriptions {#section12-2042018820937896}
--------------------------------------

The percentage of male patients being prescribed LT4 stayed steady over the observation period at approximately 1% of patients. However, the percentage of female patients being prescribed LT4 decreased significantly from 5% in 2008 to 2.9% in 2016 (see [Figure 5](#fig5-2042018820937896){ref-type="fig"}).

![Annual percentage of patients with levothyroxine (LT4) prescriptions divided according to patient sex.](10.1177_2042018820937896-fig5){#fig5-2042018820937896}

TSH values at time of LT4 prescription initiation {#section13-2042018820937896}
-------------------------------------------------

When examining the TSH values available in the patient's EMR prior to initiation of a new LT4 prescription, TSH elevations were noted to be relatively modest with mean TSH values on an annual basis ranging between 7.51 and 13.78 mIU/L (see [Table 7](#table7-2042018820937896){ref-type="table"}), with values being stable at approximately 10 mIU/L between 2014 and 2016.

###### 

Mean and median TSH value for patients prior to new LT4 prescription initiation.

![](10.1177_2042018820937896-table7)

  TSH values prior to new LT4 prescription initiation                                        
  ----------------------------------------------------- ------ ------- ------- ------ ------ ------
  2008                                                  1159   11.04   29.40   3.64   1.62   7.28
  2009                                                  1209   10.68   26.78   4.57   1.87   7.35
  2010                                                  1156   13.78   41.95   5.08   2.23   8.04
  2011                                                  2007   7.51    16.07   4.26   1.99   6.39
  2012                                                  2096   8.39    18.42   4.54   1.98   6.77
  2013                                                  2163   7.82    16.25   4.69   2.22   6.93
  2014                                                  2035   10.09   24.18   4.90   2.17   7.64
  2015                                                  1824   10.63   25.57   4.77   1.99   7.81
  2016                                                  1510   10.72   25.89   4.78   2.17   7.50

LT4, levothyroxine; pctl, percentile; TSH, thyroid stimulating hormone

Discussion {#section14-2042018820937896}
==========

In contrast to other studies or analyses which show increases in LT4 prescribing,^[@bibr8-2042018820937896],[@bibr16-2042018820937896],[@bibr17-2042018820937896],[@bibr19-2042018820937896]^ our study shows that LT4 being provided for a diagnosis of hypothyroidism remained relatively stable from 2008 to 2016. Moreover, the number of LT4 prescriptions being given to patients without a diagnosis of hypothyroidism declined over the same period. If hypothyroidism is accurately documented in the EMR of these patients, this could suggest that LT4 is being given less frequently for non-specific symptoms. The decline in LT4 prescriptions seemed to occur mostly in women. It is indeed surprising that so many LT4 prescriptions were being written for patients without a documented diagnosis of hypothyroidism. It is suspected that such patients may have been prescribed LT4 for conditions or symptoms such as obesity, tiredness, and depression.

Our analysis confirms other studies that show that LT4 prescriptions are being written for patients with relatively mild TSH elevations.^[@bibr7-2042018820937896],[@bibr12-2042018820937896],[@bibr13-2042018820937896]^ This is perhaps illustrated by the pattern of the mean and median TSH values shown in [Table 7](#table7-2042018820937896){ref-type="table"}. Although the mean TSH is mildly elevated, the median TSH is in the high end of the normal range. This could indicate that there are some individuals in the dataset that have high TSH values, possibly meriting treatment, leading to the mean TSH being above the normal range, but that there are a substantial number of patients who only have "high-normal" TSH values, thus accounting for the median TSH actually being in the higher part of the normal range. The mean TSH values prior to prescription initiation during the last 3 years of observation in our study remained steady at 10 mIU/L. It is important to note that often such mild TSH elevations have a tendency to normalize themselves, even without LT4 being initiated, as has been shown in prior studies.^[@bibr20-2042018820937896],[@bibr21-2042018820937896]^ Our study also confirms other studies that have demonstrated that LT4 initiation is prevalent in older individuals.^[@bibr14-2042018820937896]^ In the present study LT4 was most frequently initiated in those in the age groups of 50--59 years and 60--69 years but was also initiated in those of 70--79 years and in those over 80 years. Similar patterns were seen for all LT4 prescription (new and existing).

We also present new data about LT4 doses in individuals being prescribed LT4 and the effect of having or not having a diagnosis of hypothyroidism on prescribing patterns. With respect to LT4 doses, the fact that the 50 µg dose was the one most frequently prescribed, irrespective of whether or not a diagnosis of hypothyroidism had been definitely documented, further illustrates that mild degrees of hypothyroidism are being treated, or possibly that hypothyroidism was not present at all. Although the authors do not have data regarding the percentage of patients who had low TSH values following initiation of LT4, it could be hypothesized that in some patients treatment simply lowered their TSH values from the upper to the lower end of the normal range. A full replacement dose of LT4 is approximately 100 µg in someone of about 70 kg with minimal residual endogenous thyroid function. This dose was prescribed in 13.6--15.6% of those with a documented diagnosis of hypothyroidism, and 14.7--16.2% of those with no documentation of hypothyroidism.

Surprisingly, in addition to the pattern of LT4 dosage use not differing on the basis of whether a diagnosis of hypothyroidism was present or not, the ages of patients receiving LT4 did not seem to differ depending on whether a diagnosis of hypothyroidism had been formally documented or not. The mean age of initiation of LT4 prescriptions was similar regardless of whether the patient's EMR contained a diagnosis of hypothyroidism or not. Prescription initiation seemed to be prevalent across all age groups, although the number of prescriptions rose on an annual basis most notably in those of 50--69 years of age. The second most frequent age range in which LT4 was initiated was in those of 60--69 years, with substantial initiation occurring in older age groups also. This is concerning, as there are fewer data about the benefits of LT4 therapy in older age groups,^[@bibr22-2042018820937896]^ but clear risks of over-replacement.^[@bibr23-2042018820937896]^ In addition, based on age-specific reference ranges for TSH values,^[@bibr24-2042018820937896]^ it is possible that many of these older individuals may not actually have hypothyroidism. Although mild TSH elevation may be associated with cardiac dysfunction,^[@bibr25-2042018820937896]^ there may not be benefits in older individuals,^[@bibr26-2042018820937896]^ who also have additional considerations because of frailty.^[@bibr27-2042018820937896]^

Our study has several limitations. Our data are limited by any inherent inaccuracy of documentation present within the MedStar database. If patients actually did have a diagnosis of hypothyroidism, but this diagnosis was not documented, we would have incorrectly classified them as not having a diagnosis of hypothyroidism. Also, patients moving from a geographic area or physician not covered by the MedStar system might appear to have a new diagnosis of hypothyroidism with a normal serum TSH. Despite the limitations of using a health care database such as this, it is likely that the data generated are relevant and generalizable. However, the strengths of our data include the likelihood that these data are accurate: although prescriptions written by providers outside of the MedStar system would not be captured, "hand-written" prescriptions would be extremely rare due to the lack of availability of prescription pads. Due to the diverse demographics of the MedStar hospitals, we believe there is a high likelihood that these data are representative of the United States in general, with the exception of rural areas.

In summary, we have shown that although the percentage of patients being prescribed LT4 is stable or slightly declining, with most decrement in those without a diagnosis of hypothyroidism, there is nevertheless continued initiation of LT4 in those with mild degrees of TSH elevation, and in those of older age, raising concerns both about unnecessary treatment and about iatrogenic thyrotoxicosis. Such data suggest the need for great consideration of both the degree of thyroid stimulating hormone elevation and the patient context when considering whether treatment of an elevated thyroid stimulating hormone, *versus* ongoing monitoring, is indicated.

SD is a Senior Biostatistician for MedStar Health Research Institute.
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